Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 8/20 | 0.65 |
| ▸ | IGF1R | P08069 | 9/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219339 | 0.91 | ALK (0.71) | PTK2IGF1RALKEGFR | |
| SCHEMBL16998990 | 0.91 | PTK2 (0.80) | PTK2IGF1RALKEGFR | |
| SCHEMBL11919325 | 0.88 | PTK2 (0.84) | PTK2IGF1RALKEGFR | |
| SCHEMBL16998986 | 0.82 | PTK2 (0.69) | PTK2IGF1RALKEGFR | |
| SCHEMBL11919345 | 0.82 | PTK2 (0.77) | PTK2IGF1RALKEGFR | |
| SCHEMBL17410930 | 0.81 | PTK2 (0.78) | PTK2IGF1RALKEGFR | |
| SCHEMBL15219359 | 0.81 | IGF1R (0.84) | PTK2IGF1RALK | |
| SCHEMBL11919218 | 0.80 | PTK2 (0.81) | PTK2IGF1RALKEGFR | |
| SCHEMBL11916525 | 0.80 | PTK2 (0.72) | PTK2IGF1RALKEGFR | |
| SCHEMBL29710747 | 0.79 | ALK (0.64) | PTK2IGF1RALKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | PTK2 75/4885IGF1R 586/4885ALK 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.